HealthEquity (NASDAQ:HQY) updated its FY 2022 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.450-1.500 for the period, compared to the Thomson Reuters consensus estimate of $1.410. The company issued revenue guidance of $755 million-765 million, compared to the consensus revenue estimate of $755.51 million.
A number of research analysts recently weighed in on HQY shares. Robert W. Baird reiterated a hold rating and set a $86.00 price objective on shares of HealthEquity in a research note on Monday, May 24th. JPMorgan Chase & Co. assumed coverage on HealthEquity in a research report on Thursday, April 29th. They issued an overweight rating for the company. SVB Leerink increased their price objective on shares of HealthEquity from $77.00 to $80.00 and gave the company a market perform rating in a research report on Tuesday, March 16th. Raymond James lifted their target price on shares of HealthEquity from $85.00 to $90.00 and gave the stock a strong-buy rating in a report on Thursday. Finally, Cantor Fitzgerald upped their target price on shares of HealthEquity from $82.00 to $85.00 and gave the stock an overweight rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. HealthEquity currently has an average rating of Buy and a consensus price target of $82.55.
HealthEquity stock traded up $0.03 during midday trading on Thursday, reaching $77.99. 16,413 shares of the company traded hands, compared to its average volume of 750,647. HealthEquity has a 12 month low of $45.82 and a 12 month high of $93.32. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.25 and a quick ratio of 2.25. The company’s 50 day simple moving average is $74.93. The stock has a market cap of $6.50 billion, a price-to-earnings ratio of 657.17, a price-to-earnings-growth ratio of 7.49 and a beta of 1.36.
In other HealthEquity news, insider Darcy G. Mott sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, April 20th. The stock was sold at an average price of $70.31, for a total value of $421,860.00. Following the transaction, the insider now directly owns 77,052 shares of the company’s stock, valued at $5,417,526.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 18,000 shares of company stock valued at $1,315,080. 2.80% of the stock is owned by company insiders.
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Story: Mutual funds are not immune from market timing
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.